FDA Approval Makes Deciphera’s Qinlock First Fourth-Line GIST Drug
Executive Summary
Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.
You may also be interested in...
Bluebird’s Eli-Cel Gene Therapy Among Myriad New Drugs Seeking EU Approval
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Pipeline Watch: Phase III Readouts In NSCLC, Narcolepsy, Cutaneous T-Cell Lymphoma
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.